Overview

Magnesium Sulphate for Preterm Birth (MASP Study)

Status:
Completed
Trial end date:
2019-08-12
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess whether magnesium sulphate for women at risk of preterm birth can protect their children against cerebral palsy. The results from this randomised controlled trial will be added to the previous meta-analysis to obtain firm evidence for magnesium sulphate as a neuroprotector, and determine whether it should be used as standard therapy for women in preterm birth.
Phase:
Phase 3
Details
Lead Sponsor:
Hvidovre University Hospital
Treatments:
Magnesium Sulfate